Fessler, Jessica
Matson, Vyara
Gajewski, Thomas F.
Funding for this research was provided by:
National Institutes of Health (R35 CA210098)
National Cancer Institute (T32 CA009594)
American Cancer Society (Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherap)
Melanoma Research Alliance
Article History
Received: 3 November 2018
Accepted: 22 March 2019
First Online: 17 April 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: T.F.G. is an advisory board member for Roche-Genentech, Merck, Abbvie, Bayer, Aduro, and Fog Pharma. T.F.G. receives research support from Roche-Genentech, BMS, Merck, Incyte, Seattle Genetics, and Ono. T.F.G. is a shareholder/cofounder of Jounce Therapeutics. The University of Chicago holds a licensing arrangement with Evelo. T.F.G., J.F., and V.M. are inventors on U.S. patent US20160354416 A1 submitted by the University of Chicago.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.